The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PRAX | +146.73% | -62.58% | -17.83% | -58% |
| S&P | +16.9% | +95.99% | +14.39% | +95% |
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.05M | -118.4% |
| Gross Margin | 99.37% | 20.9% |
| Market Cap | $856.52M | 21.0% |
| Market Cap / Employee | $7.38M | 0.0% |
| Employees | 116 | 41.5% |
| Net Income | -$71.13M | -117.7% |
| EBITDA | -$76.02M | -103.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $157.42M | 8.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.76M | -36.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -56.16% | -13.1% |
| Return On Invested Capital | -114.78% | 9.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$54.42M | -101.6% |
| Operating Free Cash Flow | -$54.37M | -101.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.44 | 3.58 | 1.65 | 1.95 | -18.43% |
| Price to Sales | 677.02 | 179.78 | 98.18 | 116.29 | -73.55% |
| Price to Tangible Book Value | 2.44 | 3.58 | 1.65 | 1.95 | -18.43% |
| Enterprise Value to EBITDA | -12.89 | -17.94 | -6.30 | -7.93 | -30.89% |
| Return on Equity | -64.3% | -71.0% | -63.6% | -61.0% | 29.28% |
| Total Debt | $1.66M | $1.37M | $1.07M | $0.76M | -61.20% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
